US-based medical technology company HeartFlow has introduced the next generation of the HeartFlow FFRct Analysis.

The next generation platform has undergone modifications on process and algorithms which is used by HeartFlow to calculate FFRct values.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

HeartFlow chairman and CEO John Stevens said: "This is a major milestone for HeartFlow and a crucial advancement as we see increasing adoption of the HeartFlow Analysis around the world.

"The platform is now characterised with more security measures to cater to the requirement of healthcare institutions across the world."

"With this next generation platform, HeartFlow will be able to deliver results more quickly and securely to the growing number of physicians using the HeartFlow Analysis to aid in the diagnosis of coronary artery disease."

An enhanced new Heartflow platform features advanced algorithms and streamlined case processing which enables a faster generation of HeartFlow Analysis results to clinicians.

Multiple layers of nonlinear algorithms are integrated by deep learning which assists in determining patterns and thereby improving understanding of the information.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The cloud-based infrastructure of the platform uses Amazon Web Services (AWS) to ensure a secure, robust and scalable delivery of the HeartFlow service.

The platform is now characterised with more security measures to cater to the requirement of healthcare institutions across the world.

HeartFlow co-founder and chief technology officer Charles Taylor said: "One of the benefits of HeartFlow’s cloud-based platform is that the technology utilises the data we receive from our global community of clinicians."

The HeartFlow Analysis is a non-invasive technology which offers an insight into both the extent of coronary artery disease and the impact of disease on blood flow to the heart, enabling clinicians to select an appropriate treatment.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact